These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

776 related items for PubMed ID: 19799473

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
    Lyman GH, Lalla A, Barron RL, Dubois RW.
    Clin Ther; 2009 May; 31(5):1092-104. PubMed ID: 19539110
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.
    Whyte S, Cooper KL, Stevenson MD, Madan J, Akehurst R.
    Value Health; 2011 Jun; 14(4):465-74. PubMed ID: 21669371
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
    Fust K, Li X, Maschio M, Barron R, Weinstein MC, Parthan A, Walli-Attaei M, Chandler DB, Lyman GH.
    Gynecol Oncol; 2014 Jun; 133(3):446-53. PubMed ID: 24657302
    [Abstract] [Full Text] [Related]

  • 10. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
    Naeim A, Henk HJ, Becker L, Chia V, Badre S, Li X, Deeter R.
    BMC Cancer; 2013 Jan 08; 13():11. PubMed ID: 23298389
    [Abstract] [Full Text] [Related]

  • 11. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
    Hill G, Barron R, Fust K, Skornicki ME, Taylor DC, Weinstein MC, Lyman GH.
    J Med Econ; 2014 Jan 08; 17(1):32-42. PubMed ID: 24028444
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N, Isogai PK, De Angelis C, Smith TJ, Cheung M, Mittmann N, Hoch JS, Walker S.
    J Natl Cancer Inst; 2013 Aug 07; 105(15):1078-85. PubMed ID: 23873405
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.
    Gebremariam GT, Fentie AM, Beyene K, Sander B, Gebretekle GB.
    BMC Health Serv Res; 2022 Dec 30; 22(1):1600. PubMed ID: 36585648
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer.
    Aapro MS, Chaplin S, Cornes P, Howe S, Link H, Koptelova N, Mehl A, Di Palma M, Schroader BK, Terkola R.
    Support Care Cancer; 2023 Sep 20; 31(10):581. PubMed ID: 37728795
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan.
    Tseng TH, Chiang SC, Hsu JC, Ko Y.
    PLoS One; 2024 Sep 20; 19(6):e0303294. PubMed ID: 38857244
    [Abstract] [Full Text] [Related]

  • 16. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.
    Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J.
    J Manag Care Pharm; 2007 May 20; 13(4):337-48. PubMed ID: 17506600
    [Abstract] [Full Text] [Related]

  • 17. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
    Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for Research and Treatment of Cancer.
    Eur J Cancer; 2011 Jan 20; 47(1):8-32. PubMed ID: 21095116
    [Abstract] [Full Text] [Related]

  • 18. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma--a cost-effectiveness analysis.
    Numnum TM, Kimball KJ, Rocconi RP, Kilgore LC, Straughn JM.
    Int J Gynecol Cancer; 2007 Jan 20; 17(5):1019-24. PubMed ID: 17386043
    [Abstract] [Full Text] [Related]

  • 19. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
    Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Joore MA, Borm GF, Tjan-Heijnen VC.
    J Clin Oncol; 2013 Dec 01; 31(34):4283-9. PubMed ID: 24166522
    [Abstract] [Full Text] [Related]

  • 20. [Cost-effectiveness of primary prophylaxis with PEG-rhG-CSF in early-stage breast cancer patients receiving chemotherapy in China].
    Xia W, Wang SS, Hu H, Zhao FL, Xu F, Hong RX, Jiang KK, Yuan ZY, Shi YX, Zhao K, Huang JJ, Xue C, Bi XW, Lu QY, An X, Zhang JM.
    Zhonghua Zhong Liu Za Zhi; 2020 Oct 23; 42(10):861-867. PubMed ID: 33113628
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.